*Testing does not guarantee particular clinical outcomes. Results may vary and LYNPARZA may not work for everyone.
HRD testing can help identify patients with HRD-positive advanced ovarian cancer who are eligible for certain targeted therapies.1
TEST TO TREAT
Ovarian cancer is the most common cause of death among gynecologic cancers.2
Women with advanced (stage III or IV) ovarian cancer are at high (≥70%) risk of disease recurrence.3
About half of high-grade serous ovarian cancers exhibit homologous recombination deficiency (HRD); HRD status can guide treatment decisions.1,4,5
TEST TO INFORM TREATMENT DECISIONS
LYNPARZA® (olaparib) plus bevacizumab is a maintenance treatment option for select patients with homologous recombination deficiency (HRD)-positive† advanced ovarian cancer.1
LYNPARZA in combination with bevacizumab is the only maintenance combination therapy to demonstrate a clinically meaningful improvement in progression-free survival (PFS) and overall survival (OS) outcomes in patients with HRD-positive† disease after response to first-line chemotherapy, based on the PAOLA-1 clinical trial.1,6-9‡
TEST TO GUIDE PERSONALIZED THERAPY
Advanced ovarian cancer is a biomarker-driven disease. HRD testing at diagnosis is recommended by guidelines and is critical to inform an optimal treatment plan.10,11
Testing for HRD is required to identify patients eligible for LYNPARZA plus bevacizumab.1
Myriad MyChoice® CDx is the FDA-approved CDx used to identify patients with HRD-positive† disease eligible for LYNPARZA plus bevacizumab.12
†Including breast cancer gene (BRCA) mutation (as determined by Myriad MyChoice® CDx) and other causes of HRD. HRD-positive is defined as either a tumor BRCA mutation and/or an HRD score ≥42 by Myriad MyChoice® CDx.6,10
‡Prespecified exploratory analysis of PFS and secondary endpoint OS in the HRD-positive subgroup. Data based upon a prespecified exploratory subgroup analysis, which was not controlled for Type 1 error. HRD status was not a stratification factor in PAOLA-1. The analysis is based on Kaplan–Meier estimates and is descriptive only.6
HRD Testing in Advanced Ovarian Cancer
Dr Lewin and Dr Chase discuss issues surrounding HRD testing and poly (ADP-ribose) polymerase (PARP) inhibitor maintenance therapy in patients with advanced ovarian cancer.
References
- LYNPARZA® (olaparib) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2025.
- American Cancer Society (ACS). Cancer Facts & Figures 2025. Atlanta, GA; 2025. Accessed August 27, 2025. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2025/2025-cancer-facts-and-figures-acs.pdf
- Ovarian Cancer Research Alliance. Recurrence. Accessed August 27, 2025. https://ocrahope.org/patients/about-ovarian-cancer/recurrence/
- Konstantinopoulos PA, Ceccaldi R, Shapiro GI, D’Andrea AD. Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer. Cancer Discov. 2015;5(11):1137-1154.
- Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-775.
- Ray-Coquard I, Leary A, Pignata S, et al. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial. Ann Oncol. 2023;34(8):681-692.
- Hardesty MM, Krivak TC, Wright GS, et al. OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab. Gynecol Oncol. 2022;166(2):219-229.
- Monk BJ, Oaknin A, O’Malley DM, et al. LBA30 ATHENA-COMBO, a phase III, randomized trial comparing rucaparib (RUCA) + nivolumab (NIVO) combination therapy vs RUCA monotherapy as maintenance treatment in patients (pts) with newly diagnosed ovarian cancer (OC). Ann Oncol. 2024;35:S1223-S1224.
- Ellis LM, Bernstein DS, Voest EE, et al. American Society of Clinical Oncology perspective: raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol. 2014;32(12):1277-1280.
- González-Martín A, Harter P, Leary A, et al. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(10):833-848.
- Gaillard S, Lacchetti C, Armstrong DK, et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: ASCO Guideline update. J Clin Oncol. 2025;43(7):868-891.
- Myriad Genetic Laboratories, Inc. Myriad MyChoice® CDx Technical Information. Accessed June 30, 2025. https://s3.amazonaws.com/myriad-web/myChoiceCDx/downloads/myChoiceCDxTech.pdf.
Abbreviations:
CDx, companion diagnostic; FDA, US Food and Drug Administration; OS, overall survival; PFS, progression-free survival.
©2025 AstraZeneca. All rights reserved. US-99259 Last Updated 10/25
LYNPARZA is a registered trademark of the AstraZeneca group of companies.